Today, Relief Therapeutics (OTC:RLFTF) and NeuroRx (BRPA) announced that their phase 3 drug, Zyesami, IV VIP met its primary end point for recovery from respiratory failure. Overall survival was also statistically significant, according to the release.
Some of the most important take aways from this PR are:
- ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial.
- “On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration (“FDA”) for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA).”
- “We look forward to working with the National Institutes of Health, the Department of Defense, the FDA, and regulators around the world to bring this treatment to patients as quickly as possible.”
Possible Catalysts for RLFTF stock
-Near term uplisting to the NASDAQ already leaked by the CFO at the January Biotech investors fund
-OWS contract for 30k doses up front and 100k doses quarterly
-Announcement of distribution agreement with AmerisourceBergen, Cardinal and Mckesson
-EAP award for being the first drug to improve survival and respiratory failure in moderate/severe COVID
-New international agreements for distribution and EUA